BACKGROUND Roflumilast, a phosphodiesterase 4 inhibitor, has been approved for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations. It is unclear which patients will have a favourable benefit-harm balance with roflumilast. Our aim was to quantitatively assess the benefits and harms of roflumilast (500 µg/day) compared with placebo. METHODS We used summary data release...

Through various forms of support, in Bangladesh, safety net programs have been able to reach a variety population segments and help decrease poverty vulnerability. Every year, reduce hardship among the populace, Bangladeshi government affords huge amount money from national budget. These include establishing temporary jobs for men women working age, providing income stability elderly, widows, p...

Aim To analyse the cost-effectiveness of different interventions for Type 2 diabetes prevention within a common framework. Methods A micro-simulation model was developed to evaluate the cost-effectiveness of a range of diabetes prevention interventions including: (1) soft drinks taxation; (2) retail policy in socially deprived areas; (3) workplace intervention; (4) community-based intervention;...

AIM To analyse the cost-effectiveness of different interventions for Type 2 diabetes prevention within a common framework. METHODS A micro-simulation model was developed to evaluate the cost-effectiveness of a range of diabetes prevention interventions including: (1) soft drinks taxation; (2) retail policy in socially deprived areas; (3) workplace intervention; (4) community-based interventio...

INTRODUCTION Health-care technologies (HCTs) play an important role in any country's health-care system. Zimbabwe's health-care system uses a lot of HCTs developed in other countries. However, a number of local factors have affected the absorption and use of these technologies. We therefore set out to test the hypothesis that the net benefit regression framework (NBRF) could be a helpful benefi...

The literature on treatment effects focuses on gross benefits from program participation. We extend this literature by developing conditions under which it is possible to identify parameters measuring the cost and net surplus from program participation. Using the generalized Roy model, we nonparametrically identify the cost, benefit, and net surplus of selection into treatment without requiring...